AstraZeneca shares jump as stock buying pressure builds

Traders Union
All News
Financial News
Astrazeneca surges 2.17% today

Highlights

AstraZeneca expanded its oncology portfolio by completing an early-stage trial of AZD9829 for CD123+ blood cancers.
The company announced a partnership with Abbisko Therapeutics to advance a novel lung cancer therapy with Phase I/II trials planned in China.
Share price exhibits bullish momentum with buyers dominating, trading near GBX14,154 within a projected range of GBX13,602–GBX14,501 over the next week.

Share count rises and oncology trials expand amid collaboration

AstraZeneca admitted 14,784 new ordinary shares from employee schemes to trading on the London Stock Exchange, increasing the total number of shares in issue to 1,551,024,534. The company also expanded its oncology pipeline by completing an early-stage trial of AZD9829 for CD123+ hematologic cancers. Additionally, AstraZeneca entered a collaboration with Abbisko Therapeutics to develop a novel combination therapy for non-small cell lung cancer, with a Phase I/II trial planned in China.

Anton Kharitonov, expert at Traders Union, views the rally in AstraZeneca as driven by headline optimism and technical alignment. He cautions that while news of pipeline expansion and new shares adds interest, underlying signals reveal mixed momentum and weakening trend strength. Kharitonov notes that positive indicators like MACD and strong buyer dominance may not override the warning from ADX and oscillators flashing early caution. He believes the upside may be vulnerable due to overbought conditions and high intraday volatility. "I see the bullish setup as fragile — short-term traders should remain defensive as sentiment can shift quickly."

Viktoras Karapetjanc, expert at Traders Union, highlights the strength of AstraZeneca’s fundamentals after the new oncology pipeline additions and employee share issuance. He sees the bullish chart structure as confirming market confidence and positioning the company for further growth. Karapetjanc believes the collaboration with Abbisko Therapeutics underscores AstraZeneca's innovation and global ambitions. "This bullish structure remains intact, and I expect AstraZeneca to unlock new highs if momentum continues above GBX14,501."

Jainam Mehta, market strategist, notes the alignment of major moving averages points to a persistent trend, but observes weakening ADX and mixed momentum signals. He considers the upside gap a catalyst for tactical trades but warns of potential short-term mean reversion. Mehta suggests traders watch for a breakout or reversal near GBX14,501 for adaptive positioning. "A decisive close above resistance could trigger a breakout trade, while a pullback toward GBX13,898 may invite tactical contrarian entries."

Bullish structure holds as mixed momentum tempers intraday gains

AstraZeneca is trading above all major moving averages, with the current price at GBX14,154 against the MA-20 at GBX13,651, the MA-50 at GBX13,728, and the MA-200 at GBX13,693. This alignment affirms a bullish structure in short-, medium-, and long-term trends, reinforced by a bullish MA-50 vs MA-200 configuration, while the nearest technical levels to watch are the near-term floor at GBX13,898 and the ceiling at GBX14,501. Momentum signals are mixed. The Moving Average Convergence Divergence (MACD) and Commodity Channel Index (CCI) both forecast buying pressure, and the Relative Strength Index (RSI) at 52.26 supports a "Buy" stance with no immediate overbought condition. However, the Average Directional Index (ADX) points to weakening trend strength, and Hull Moving Average (HMA) also suggests some short-term selling. Bull/Bear Power (BBP) is strongly positive at 408.58, indicating buyers currently dominate but forecasts an overbought market. The Awesome Oscillator (AO) supports the current upward move, while Stochastic RSI remains neutral. The stock is up GBX300 or 2.17% on the day after an upside gap of 88 points (0.64%), now trading near session highs with intraday volatility at 1.84%. Price action shows robust strength toward the highs, consistent with intraday bullish momentum, even as some oscillators flash early caution.

Earlier, analysts noted that AstraZeneca's strategic positioning in oncology and recent regulatory advances underpinned expectations of continued revenue growth amid mixed technical signals. The latest rally, driven by pipeline progress and a strong technical breakout above major moving averages, strengthens the bullish case, but traders should watch for a decisive move above GBX14,501 to confirm sustained upward momentum.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.